Kayadibi Yasemin, Kılıç Fahrettin, Yılmaz Ravza, Velidedeoğlu Mehmet, Öztürk Tülin, Tekcan Deniz Esin, Ure Esmerer Emel, Aydoğan Fatih, Yılmaz Mehmet Halit
Clinic of Radiology, Gaziosmanpaşa Training and Research Hospital, İstanbul, Turkey.
Department of Radiology, Kuanta Biosibernetik Health Theraphies, İstanbul, Turkey.
Eur J Breast Health. 2020 Dec 24;17(1):1-9. doi: 10.5152/ejbh.2020.5663. eCollection 2021 Jan.
This study aimed to introduce an alternative pre-biopsy confirmation technique that combines sonography-guided intra-lesional contrast injections and single non-enhanced magnetic resonance imaging (MRI) pulse sequence in order to identify sonographic correlates of incidentally detected breast MRI lesions which were occult on primary ultrasonography (USG) and mammography examination.
From May 2014 through May 2015, a total of 37 incidental breast lesions of 37 patients, which were detected by breast MRI, were evaluated with targeted second look ultrasound (SLUS). The suspected lesion on USG was marked with a gadolinium-based contrast agent under USG guidance. After a single non-enhanced T1 weighted control MR sequence, positively correlated lesions with initial MRI were sampled by USG guided core biopsy.
Of the 37 lesions evaluated, 32 (86%) lesions showed a correlation between MRI and SLUS findings. On SLUS core biopsy, there were eight (25%) malignant and 11 (34.4%) high-risk lesions among these 32 cases with correlated MRI findings; while the remaining 13 (40.6%) cases had benign histopathology. Eleven (34.4%) of the SLUS-discovered lesions were focus, 11 (34.4%) were non-mass enhancements, and the remaining 10 (31.2%) were mass lesions. Of the five lesions (13.5%) that showed no correlations on MRI and SLUS examinations, four were non-mass enhancements and one was focus.
SLUS represents a method for identifying MRI-detected lesions and provides a bridge to ultrasound-guided biopsy for histopathological diagnosis. There is a need for confirmation of biopsies to avoid false negative results. We describe a cheap, safe, and easy-to-apply USG-guided pre-biopsy lesions marking method in order to ensure definite correlation.
本研究旨在引入一种替代性的活检前确认技术,该技术将超声引导下病灶内造影剂注射与单次非增强磁共振成像(MRI)脉冲序列相结合,以识别在初次超声检查(USG)和乳腺X线摄影检查中隐匿的偶然发现的乳腺MRI病灶的超声相关特征。
2014年5月至2015年5月,对37例患者经乳腺MRI检测出的37个偶然发现的乳腺病灶进行了靶向二次超声检查(SLUS)评估。在超声引导下,用钆基造影剂标记超声检查中疑似的病灶。在单次非增强T1加权对照MR序列后,通过超声引导下的粗针活检对与初始MRI呈正相关的病灶进行取样。
在评估的37个病灶中,32个(86%)病灶的MRI和SLUS结果显示有相关性。在SLUS粗针活检中,这32例MRI结果相关的病例中有8个(25%)为恶性病灶,11个(34.4%)为高危病灶;其余13例(40.6%)病例组织病理学为良性。SLUS发现的病灶中,11个(34.4%)为局灶性,11个(34.4%)为非肿块强化,其余10个(31.2%)为肿块性病灶。在MRI和SLUS检查中无相关性的5个病灶(13.5%)中,4个为非肿块强化,1个为局灶性。
SLUS是一种识别MRI检测到的病灶的方法,并为超声引导下活检进行组织病理学诊断提供了桥梁。需要对活检进行确认以避免假阴性结果。我们描述了一种廉价、安全且易于应用的超声引导下活检前病灶标记方法,以确保明确的相关性。